about
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisInterventions in the management of serum lipids for preventing stroke recurrenceUpdate on Inflammatory Biomarkers and Treatments in Ischemic StrokeStatins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory studyPossible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factorsAll cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.MicroRNA in ischemic stroke etiology and pathology.Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease.Pharmacology and clinical experience with simvastatin.Lipids and atherosclerosis: clinical management of hypercholesterolaemia.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyStatins in the 21st century: end of the simple story?Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention.Interventions in the management of serum lipids for preventing stroke recurrence.Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS)Stroke prevention: what's new?Statins for the prevention of stroke: a meta-analysis of randomized controlled trials.Potential nontraditional applications of statins.The many roles of statins in ischemic strokeLipid levels and the risk of ischemic stroke in women.Low total cholesterol level is the independent predictor of poor outcomes in patients with acute ischemic stroke: a hospital-based prospective studyThe association between serum adhesion molecules and outcome in acute spontaneous intracerebral hemorrhage.Clinical neuroprotective drugs for treatment and prevention of stroke.The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study.Treatment with statins in the acute phase of ischemic stroke.Stroke prevention with lipid-lowering therapy.The role of statins in preventing stroke.Characteristics of subjects with very low serum low-density lipoprotein cholesterol and the risk for intracerebral hemorrhageStatins in stroke: prevention, protection and recovery.Stroke prevention and statin treatment.Histopathology of carotid atherosclerotic disease.Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.Statin use and risk of prostate cancer: results from a population-based epidemiologic study.Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts.Secondary stroke prevention: patent foramen ovale, aortic plaque, and carotid stenosis.Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherence.The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Trial: Where to Now?The devil is in the details.Role of factor XIII Val 34 Leu polymorphism in patients with migraine.Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus.
P2860
Q24194514-28636C33-C436-4843-922F-7E4F9EC39838Q24240060-D03B7033-8066-4E53-A933-867E3C90A3D3Q28078744-1168836A-7A0B-4EC2-9D3F-BF7AB6159BABQ30417962-A30AFE90-2AA1-4578-8BD7-884B09069EF8Q30814231-C034268B-6402-44FE-8528-A7EBED1BE3F3Q31101617-2968AE16-5D3A-4431-8750-53CEDE91EA8AQ34137995-CE8AC4A3-92C9-43C6-A0EF-C19FA6DCB2F6Q34189648-F105CD8B-00EB-4EC4-B81F-092EE422B251Q34240784-35F636C3-3D83-480C-A0E9-A78140ED5CF4Q34240879-8B049C34-EB3A-46BC-B7DD-07E6D3936FC1Q34386587-BCCB2BD5-BECD-44F3-803B-D4E9C28F6DCDQ34481748-611AFCB9-E8F5-4733-98B0-100CE12DB452Q34530349-83414FFD-121A-4DB7-ACFD-888813DFA3FAQ34757974-60CB7E03-0F57-44C0-AAF8-63D6EE507A97Q34819418-C367D932-4481-424F-B847-73AA3421876FQ35101655-74C90876-CE08-42A6-AC4B-F3E7A3A43428Q35124353-8D6C21BE-9F1C-4801-BDD9-3B573D434A3BQ35169445-795C4A8F-64BE-4A7F-A3AF-7E21D1862131Q35595431-CCB496F0-1FA7-4C0E-B32F-CD4D5BA68CCCQ35652626-B72ACF06-81A5-4BC1-830C-01826FED2B1AQ35958848-52699E7B-2EA9-4F57-8553-F538A4D77B62Q36073088-DD16E463-6B65-47A7-BCB5-089530E14654Q36097037-2EEC8082-E3A8-444A-B693-CBC565122EDAQ36106351-6B19146A-2CDD-4AA8-B0A6-1C4767545FA0Q36106811-73F3FFFD-140D-4535-9C05-E24D904083CDQ36107099-F354DD99-EDEE-4604-B056-BE7F153239FFQ36110439-945C6E54-9349-4DC0-A86A-0C32C5B65DABQ36237971-05C9E35C-E853-452E-B3A2-18A1E6C4AF51Q36390817-3BBF40E6-BE7D-4509-BC48-207ECC7B8408Q36533155-2E3AA0C0-DFA6-44D7-A604-894D9C2EBE2CQ36629746-6A0FF144-1449-4875-8514-1871F54A89B0Q36817063-4D8F3253-7138-41CB-8FA3-B30F1E98C3C9Q36978974-1CC96F86-108B-48E8-89B8-5D9FBB85CF79Q37098888-78481932-86E1-4975-9142-E9C93EB18A69Q37994168-80DEDC44-0974-4DC4-B72D-4935C74C776AQ39755456-D5D60B6D-D16C-4649-B67B-548B6A15EE41Q43056005-B5571956-5EA5-4183-929E-CAE463C84CC8Q43645742-5E494F82-04AE-48C6-8A7E-9D2544EF640CQ43817848-CA3EA16F-0E15-4516-B8BE-7D0C7B3E5C5AQ44687349-108ABFC3-E417-4DFA-A9F0-30E453D6E443
P2860
description
article
@en
im August 2000 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2000
@uk
name
Pravastatin Therapy and the Risk of Stroke
@en
Pravastatin Therapy and the Risk of Stroke
@nl
type
label
Pravastatin Therapy and the Risk of Stroke
@en
Pravastatin Therapy and the Risk of Stroke
@nl
prefLabel
Pravastatin Therapy and the Risk of Stroke
@en
Pravastatin Therapy and the Risk of Stroke
@nl
P2093
P50
P1476
Pravastatin Therapy and the Risk of Stroke
@en
P2093
Adrienne C. Kirby
Andrew M. Tonkin
David Hunt
David M. Colquhoun
Harvey D. White
Malcolm J. West
Neil E. Anderson
R. John Simes
Stephen MacMahon
P304
P356
10.1056/NEJM200008033430502
P407
P577
2000-08-03T00:00:00Z